乳腺癌辅助化疗的新进展

辅助化疗、内分泌治疗对乳腺癌远期无瘤生存率和总生存率有明显提高。目前乳腺癌辅助化疗应用最多的仍是蒽环类及紫杉类药物。已证明,单用紫杉类比单用蒽环类药物疗效更好。由于具有不同的抗癌机制,紫杉类与蒽环类联用可取得更好疗效。对于乳腺癌的辅助治疗,如何选择给药方式、给药密度,以达到最佳的远期疗效是目前关注的焦点之一。此外,利用生物标志物对临床早期乳腺癌预后的指导作用,在化疗及内分泌治疗中进行合理取舍,提高疗效、降低复发及治疗风险,也是目前的研究方向。

New advances of adjuvant chemotherapy in breast cancer

It's widely accepted that adjuvant chemotherapy and endocrine treatment significantly improved DDFS and OS in breast cancer . Nowaday, The chemotherapeutic drugs of anthracycline and taxane are used widely in breast cancer. It was proved that taxane alone can get more benefit than anthracycline alone in breast cancer. The combining chemotherapy of anthracycline and taxane can improve clinical outcomes because of their different anticancer mechanism, but how to use them perfectly is a hot topic. Another interesting avenue of investigation regarding adjuvant therapy relates to the utilization of prognostic and predictive biomarkers to quantify risk for recurrence and to identify populations of patients who benefit more or less from treatment in adjuvant chemotherapy of early-Stage breast cancer .